Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.

While pausing therapy did not affect response to vaccination, the investigators noted that participants who paused therapy did have higher rates of self-reported lymphadenopathy. | Image credit: Konstantin Yuganov - stock.adobe.com

Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

By Jared Kaltwasser

April 18th 2025

Previous work had suggested pausing Bruton tyrosine kinase (BTK) inhibitors before COVID-19 vaccination might boost immunity in patients with chronic lymphocytic leukemia (CLL).

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

By Jared Kaltwasser

April 15th 2025

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

By Jared Kaltwasser

April 10th 2025

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.

Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com

Immune Microenvironment a Key Target in CLL

By Jared Kaltwasser

April 8th 2025

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

<1 2 3 4 5

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions